New Breakthrough Treatment for Kidney Disease
| Onkareshwar Pandey - 15 Apr 2019

Good News for 70 million Diabetes Patients in India Too

Hope for Hundreds of Millions of People with Diabetes Worldwide

By Onkareshwar Pandey

New Delhi, April 15, 2019: A new Breakthrough has been achieved in the medical-science, which can be good news for around 70 million people in India, who have diabetes and, out of which up to 40% will go onto develop kidney disease.

 A new treatment for people with diabetes and kidney disease reduced kidney failure rates by a third, according to a landmark study.

The results, which were presented at the ISN World Congress of Nephrology in Melbourne today, can be implemented immediately as the drug is already available.

The results, published in the New England Journal of Medicine, also showed heart failure was reduced by over 30%, and major cardiovascular events by about 20%, according to a press release issued here in Delhi by The George Institute India.

The randomised study was funded by Janssen, which manufactures canagliflozin, and led by an independent, academic-led Steering Committee.

The drug canagliflozin was developed to lower glucose levels for people with diabetes but today has been shown to protect against kidney failure. It also significantly reduced the risk of cardiovascular complications including heart failure, which are common among people with kidney disease.

Lead author Professor Vlado Perkovic, of The George Institute for Global Health, said there was an urgent need for this new treatment given the surging rates of diabetes.

“Diabetes is the leading cause of kidney failure worldwide but for almost two decades there have been no new treatments to protect kidney function. This definitive trial result is a major medical breakthrough as people with diabetes and kidney disease are at extremely high risk of kidney failure, heart attack, stroke and death. We now have a very effective way to reduce this risk using a once-daily pill.”

The study recruited 4,401 patients with diabetes and kidney disease from 34 countries. Half were given canagliflozin on top of best available current care for kidney disease – using either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The control group received the best available care according to current guidelines, and a placebo.

Key Findings

  • The number of people developing kidney failure or dying from either renal failure or cardiovascular disease was reduced by 30%.
  • Hospitalisation for heart failure was reduced by 39%.
  • The risk of major cardiovascular outcomes  - (heart attack, stroke and cardiovascular death) was reduced by 20%
  • There was no increased risk of major side effects.

Professor Vivekanand Jha, Executive Director of The George Institute India and President of the International Society of Nephrology, said: “What the trial has shown is that this drug not only protects people with diabetes from developing kidney failure, but it also protects them from heart disease, heart failure and other cardiovascular complications. Importantly, it helps people who already have reduced kidney function and are at particularly high risk.

“With five million people predicted to have kidney failure by 2035 this is a major breakthrough.”

The researchers found the drug canagliflozin, a sodium glucose transporter 2 (SGLT2) inhibitor, was less effective at lowering blood sugar in people with reduced kidney function but still led to less kidney failure, heart failure and cardiovascular events such as heart attacks, strokes. and death from cardiovascular disease.

Professor Perkovic said the results were impressive. “The substantial benefit on kidney failure despite limited effects on blood glucose suggest that these drugs work in a number of different ways beyond their effects on blood sugar. This is an area of intense ongoing research.” 

(Onkareshwar Pandey is Editor in Chief & CEO - Indian Observer Post. He is a former Senior Group Editor- Rashtriya Sahara (Hindi & Urdu) and also former Editor - News, ANI. http://bit.ly/2mh7hih).

FOLLOW US ON FACEBOOK - https://bit.ly/2SlmpLA

FOLLOW US ON FACEBOOK - https://bit.ly/2OacnaL   

IOP ON THE GLOBAL PLATFORM FOR MEDIA BUYING - https://bit.ly/2Y06pyk

IOP TEAM BUREAUS & OUR ESTEEMED WRITERS - https://bit.ly/2LxOU2I


---------------------------------------------------------------------------------------------------------------------------------------------------------------

INDIAN OBSERVER POST (IOP) is a Class, Creative, and Constructive News platform which publishes ONLY exclusive and Special News / Views / Interviews / Research Articles / Analysis / Columns / Features and Opinions on the national and international issues, politics, security, energy, innovation, infrastructure, rural, health, education, women, and entertainment. Email – editor@indianobserverpost.com


INDIAN OBSERVER POST (Eng) -www.indianobserverpost.com

INDIAN OBSERVER POST (Hindi) -www.indianobserverpost.in

IOP ON FACEBOOK - https://bit.ly/2SlmpLA

IOP TEAM BUREAUS & WRITERS - https://bit.ly/2LxOU2I

---------------------------------------------------------------------------------------------------------------------------------------------------------------

(Onkareshwar Pandey is Founder, Editor in Chief & CEO, Indian Observer Post and former Senior Group Editor- Rashtriya Sahara (Hindi & Urdu) and also former Editor, (News), ANI. http://bit.ly/2mh7hih Email - SMS- 9910150119)


---------------------------------------------------------------------------------------------------------------------------------------------------------------

GOLDEN SIGNATURES RESEARCH & CONSULTING (GSRC)

CONTACT US FOR -COFFEE TABLE BOOKS I KNOWLEDGE EVENTS I PR I ADVERTISING I BRAND BUILDING I DIGITAL TRANSFORMATION I VIDEO CONTENT I SOCIAL MEDIA I EXTERNAL COMMUNICATIONS I SECTOR EXPERTISE I GLOBAL OUTREACH I MARKET SURVEY I And - GOLDEN SIGNATURE AWARDS I E -goldensignatures20@gmail.com

---------------------------------------------------------------------------------------------------------------------------------------------------------------

Browse By Tags



Latest News